A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy

BACKGROUND: Anlotinib is an oral anti-angiogenesis inhibitor targeting vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors, fibroblast growth factor receptors, etc., and its clinical value in cervical cancer is rarely reported. We designed a retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hui, Sun, Shaoxing, Mei, Zijie, Xiang, Qingming, Yang, Chunxu, Chen, Min, Xie, Conghua, Zhou, Yunfeng, Qiu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605803/
https://www.ncbi.nlm.nih.gov/pubmed/34815663
http://dx.doi.org/10.2147/DDDT.S335870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605803/
https://www.ncbi.nlm.nih.gov/pubmed/34815663
http://dx.doi.org/10.2147/DDDT.S335870

Ejemplares similares